Dengue Clinical Trial
Official title:
Demonstration of an Electronic Clinical Decision Support Module for Dengue Case Management and Reporting in Burkina Faso
The Integrated Management of Childhood Illness (IMCI) guideline has been implemented in
Burkina Faso and is used across primary health facilities to assess children under the age of
5 years. A part from a rapid diagnostic test (RDT) for malaria, no other point of care in
vitro diagnostic tests are widely used to improve disease diagnosis and inform treatment
decisions. Dengue fever has been reported in Burkina Faso since 1925 and the recent epidemics
in 2016 and 2017 have prompted the government to validate and deploy a clinical management
algorithm for Dengue and a case reporting process to support surveillance for a targeted
response.
The organisation Terre des hommes has digitalised IMCI and implemented the module through its
Integrated electronic Diagnosis Approach (IeDA) programme across primary health care centers
(PHCs) in the country with proven impact on clinical care and proven reduction in antibiotic
prescriptions. Many recognize the need to update the IMCI guideline with current evidence.
However this is challenging and may require large clinical trials. The advantage of
electronic clinical decision support systems is plural: they improve quality of care through
increased adherence and feedback information to the system; they strengthen surveillance
systems by connecting relevant patient related data and provide geo-tagged coordinates for
targeted responses; and they can become evidence-adaptive.
An electronic module of the Burkina Faso Dengue clinical management guideline accompanied
with dengue rapid diagnostic tests has the potential to improve the diagnosis of non-malaria
fevers in particular during "dengue seasons" and improve the efficiency of surveillance for
this disease.
In this study, the investigators aim to assess the usability and the performance of the
dengue module for patient management in primary health care facilities.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321264 -
Educational Intervention to Promote Control Behaviors and Prevention of Dengue
|
N/A | |
Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT01391819 -
Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
|
N/A | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02833584 -
Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
|
N/A | |
Completed |
NCT02433652 -
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
|
Phase 1 | |
Enrolling by invitation |
NCT02016027 -
Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
|
Phase 1 | |
Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
Recruiting |
NCT00377754 -
Prospective Study of Infant Dengue
|
N/A | |
Recruiting |
NCT05919277 -
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
|
||
Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
Completed |
NCT03803618 -
Dengue Effectiveness Study in the Philippines
|
||
Active, not recruiting |
NCT05967455 -
Homologous Re-infection With Dengue 1 or Dengue 3
|
Phase 1 | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Recruiting |
NCT02606019 -
The Use of Biomarkers in Predicting Dengue Outcome
|
N/A | |
Completed |
NCT02372175 -
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
|
Phase 1 | |
Active, not recruiting |
NCT01696422 -
Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
|
Phase 2 | |
Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
Completed |
NCT00375726 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
|
Phase 1 | |
Completed |
NCT05153018 -
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
|
N/A |